We've found
9,829 Lymphoma
clinical trials
We've found
9,829 Lymphoma
clinical trials
Oncology Clinical Trial
Updated: 12/31/1969
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials

Diffuse Large B-Cell Lymphoma Clinical Trial
Updated: 12/31/1969
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Diffuse Large B-Cell Lymphoma Clinical Trial
Updated: 12/31/1969
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Diffuse Large B-Cell Lymphoma Clinical Trial
Updated: 12/31/1969
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Diffuse Large B-Cell Lymphoma Clinical Trial
Updated: 12/31/1969
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology, Rheumatology Clinical Trial
Updated: 12/31/1969
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Sym021 Monotherapy and in Combination With Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Sym021 Monotherapy and in Combination With Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma Clinical Trial
Updated: 12/31/1969
A Study of Parsaclisib in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Relapsed/Refractory Follicular Non-Hodgkin Lymphoma Clinical Trial
Updated: 12/31/1969
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma Clinical Trial
Updated: 12/31/1969
A Study of Parsaclisib in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma Clinical Trial
Updated: 12/31/1969
A Study of Parsaclisib in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma Clinical Trial
Updated: 12/31/1969
A Study of Parsaclisib in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Cutaneous T Cell Lymphoma Clinical Trial
Updated: 12/31/1969
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Hodgkin's Disease Clinical Trial
Updated: 12/11/2017
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
Status: Enrolling
Updated: 12/11/2017
Click here to add this to my saved trials

Hematology, Oncology, Orthopedics / Podiatry Clinical Trial
Updated: 12/31/1969
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma Clinical Trial
Updated: 12/31/1969
An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Diffuse Large B-Cell Lymphoma Clinical Trial
Updated: 12/31/1969
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Diffuse Large B-Cell Lymphoma Clinical Trial
Updated: 12/31/1969
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Neoplasms Clinical Trial
Updated: 12/31/1969
A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Hodgkin's Disease Clinical Trial
Updated: 12/31/1969
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Hodgkin's Disease Clinical Trial
Updated: 12/31/1969
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Hodgkin's Disease Clinical Trial
Updated: 12/31/1969
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Hodgkin's Disease Clinical Trial
Updated: 12/31/1969
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma Clinical Trial
Updated: 1/5/2018
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
Status: Enrolling
Updated: 1/5/2018
Click here to add this to my saved trials

Treatment Naive Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Treatment Naive Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Treatment Naive Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Clinical Trial
Updated: 12/31/1969
Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma Clinical Trial
Updated: 12/31/1969
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma Clinical Trial
Updated: 12/31/1969
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

High-risk Diffuse Large B-Cell Lymphoma Clinical Trial
Updated: 12/31/1969
Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

High-risk Diffuse Large B-Cell Lymphoma Clinical Trial
Updated: 12/31/1969
Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) Clinical Trial
Updated: 12/31/1969
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) Clinical Trial
Updated: 12/31/1969
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Lymphoma, Non-Hodgkin Clinical Trial
Updated: 12/31/1969
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Central Nervous System Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Voraxaze in Patients With Central Nervous System Lymphoma
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
